Clinical Study

AGR2 Predicts Tamoxifen Resistance in Postmenopausal Breast Cancer Patients

Figure 2

Illustration of immunohistochemical detection of AGR2 protein in Tru-Cut needle biopsies. (a) IHC score 80, (b) IHC score 100, (c) IHC score 180, and (d) IHC score 220. As cut-off level determined by ROC analysis was 110, samples (a) and (b) were classified in group denoted as “low” and AGR2 expression and samples (c) and (d) were included in group denoted as “high” AGR2 expression.
761537.fig.002